CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on September 15, 2017
CELLECTAR BIOSCIENCES, INC.
3301 Agriculture Drive
Madison, WI 53716
September 15, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Christine Westbrook
| Re: | Cellectar Biosciences, Inc. | |
| Registration Statement on Form S-3 | ||
| File No. 333-218514 |
Ladies and Gentlemen:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Cellectar Biosciences, Inc., a Delaware corporation (the “Company”), hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (Registration No. 333-218514), as amended, be accelerated so that the Registration Statement will become effective at 4:00 p.m. on September 15, 2017, or as soon as practicable thereafter.
The cooperation of the staff in meeting our request is very much appreciated. If you have any questions or comments, please contact Gregory J. Lynch of Michael Best & Friedrich LLP at (608) 283-2240 or gjlynch@michaelbest.com. Thank you for your assistance with these matters.
|
Very truly yours, |
|||
| CELLECTAR BIOSCIENCES, INC. | |||
| By: | /s/ James V. Caruso | ||
| James V. Caruso, President and Chief Executive Officer | |||
| cc: |
John P. Hamill Gregory J. Lynch |